Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 16/20 | 0.51 |
| ▸ | BRAF | P15056 | 16/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1523408 | 0.93 | RAF1 (0.55) | MAPTLMNARAF1BRAF | |
| SCHEMBL1016836 | 0.92 | MAP3K5 (0.47) | MAPTLMNARAF1BRAFGAA | |
| SCHEMBL1018765 | 0.91 | MAPT (0.48) | MAPTLMNARAF1BRAFGAA | |
| SCHEMBL1017984 | 0.90 | MAPT (0.48) | MAPTLMNARAF1BRAFSMN1; SMN2 | |
| SCHEMBL1524307 | 0.90 | NPC1 (0.52) | MAPTRAF1BRAFGAA | |
| SCHEMBL1524057 | 0.89 | MAPT (0.51) | MAPTLMNARAF1BRAF | |
| SCHEMBL1015934 | 0.88 | MAP3K5 (0.43) | MAPTLMNARAF1BRAFSMN1; SMN2 | |
| SCHEMBL1523969 | 0.88 | RAF1 (0.48) | RAF1BRAFSMN1; SMN2 | |
| SCHEMBL1523767 | 0.88 | RAF1 (0.47) | RAF1BRAF | |
| SCHEMBL13654272 | 0.88 | RAF1 (0.47) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921358-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | claimed |
| US-20130203731-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2013-08-08 | — | — | US | claimed |
| US-8461163-B2 | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | claimed |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | claimed |
| US-8921358-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8921358-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20130203731-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203731-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2013-08-08 | — | — | US | disclosed |
| US-8461163-B2 | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461163-B2 | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2271646-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203731-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAPT 1024/4885LMNA 1347/4885RAF1 103/4885 |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAPT 1079/4885LMNA 1303/4885RAF1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.